Fulcrum Therapeutics, Inc. (FULC)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 11:44AM EDT. Market open.
| Previous close | 7.71 |
| Open | 7.73 |
| Bid | 7.59 x 100 |
| Ask | 7.68 x 100 |
| Day's range | 7.53 - 7.74 |
| 52-week range | 2.65 - 13.70 |
| Volume | |
| Avg. volume | 632,209 |
| Market cap | 474.854M |
| Beta (5Y monthly) | 2.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.59 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.78 |
ZacksThe Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
ZacksBiotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
ZacksWall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
The consensus price target hints at a 69.2% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
© 2024 Yahoo. All rights reserved.